Suppliers and packagers for generic pharmaceutical drug: XENON XE-133

XENON XE-133

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Curium	XENON XE 133	xenon xe-133	GAS;INHALATION	018327	NDA	Curium US LLC	69945-097-11	1 CAN in 1 CONTAINER (69945-097-11) / 1 BOTTLE in 1 CAN / 2 mL in 1 BOTTLE	2016-03-30
Curium	XENON XE 133	xenon xe-133	GAS;INHALATION	018327	NDA	Curium US LLC	69945-097-13	3 CAN in 1 CONTAINER (69945-097-13) / 1 BOTTLE in 1 CAN / 2 mL in 1 BOTTLE	2016-03-30
Curium	XENON XE 133	xenon xe-133	GAS;INHALATION	018327	NDA	Curium US LLC	69945-097-15	5 CAN in 1 CONTAINER (69945-097-15) / 1 BOTTLE in 1 CAN / 2 mL in 1 BOTTLE	2016-03-30

Xenon Xe-133: Supplier Landscape and Patent Landscape Analysis

Last updated: February 19, 2026

This report analyzes the supply chain and patent landscape for Xenon Xe-133, a critical radioisotope used in medical imaging and therapy. The analysis identifies key suppliers, patent trends, and emerging technologies relevant to its production and application.

Who Are the Primary Suppliers of Xenon Xe-133?

The global supply of Xenon Xe-133 is concentrated among a limited number of specialized producers, primarily due to the complex and regulated nature of radioisotope production. These suppliers operate under stringent licensing and safety protocols.

• Isotrak (a subsidiary of Curium): Isotrak is a significant producer and distributor of radiopharmaceuticals, including Xenon Xe-133. The company operates production facilities and a robust distribution network to serve medical institutions. Their operations are subject to regulatory oversight by bodies such as the U.S. Nuclear Regulatory Commission (NRC).
• Navidea Biopharmaceuticals: While Navidea's primary focus is on therapeutic radiopharmaceuticals, they have been involved in the development and potential supply of diagnostic agents, which can include radioisotopes like Xenon Xe-133. Their strategic partnerships and R&D activities indicate a potential role in this market.
• Eckert & Ziegler Radiopharma GmbH: This German company is a key player in the radiopharmaceutical sector, producing and distributing a range of radioisotopes for medical applications. Their expertise in handling and producing radioactive materials positions them as a potential supplier for Xenon Xe-133, particularly within the European market.
• Nordion (now part of Sterigenics): Historically, Nordion was a major global supplier of medical isotopes. Following its acquisition by Sterigenics, the combined entity continues to play a role in the isotope market, potentially including Xenon Xe-133. Their extensive experience in radioisotope production and distribution is a key asset.

Production of Xenon Xe-133 typically involves irradiating stable Xenon-132 with neutrons, a process requiring access to nuclear reactors. The purification and handling of the resulting radioactive Xenon isotope necessitate specialized facilities and expertise. The supply chain is characterized by long lead times, stringent quality control, and a high degree of regulatory compliance to ensure patient safety and environmental protection. The reliance on a small number of producers means that disruptions in production or supply chain issues can have a significant impact on the availability of Xenon Xe-133 for medical use.

What Are the Key Applications of Xenon Xe-133?

Xenon Xe-133's physical properties, particularly its gamma ray emission and gaseous form, make it suitable for specific diagnostic and therapeutic applications in medicine.

• Pulmonary Imaging (Ventilation Studies): This is the most common application. Patients inhale Xenon Xe-133 gas, and its distribution within the lungs is monitored using gamma cameras. This allows physicians to assess lung function, detect air trapping, and evaluate conditions like chronic obstructive pulmonary disease (COPD), pulmonary embolism, and interstitial lung disease. The gas's ability to freely move within the airways provides a direct measure of ventilation.
• Cerebral Blood Flow Studies: Xenon Xe-133 can be used to measure blood flow in the brain. The gas is inhaled or injected, and its uptake and clearance by brain tissue are monitored. This technique helps diagnose conditions affecting cerebral perfusion, such as stroke, cerebrovascular disease, and dementia. It provides regional blood flow information, crucial for understanding localized brain function.
• Radiosurgery and Radiotherapy (Emerging Applications): While less common than diagnostic uses, research is exploring the therapeutic potential of Xenon Xe-133. Its radioactive decay can deliver targeted radiation, and ongoing studies investigate its efficacy in treating certain types of cancer. This area of application is still under development and requires further clinical validation.
• Research Tool: Beyond direct medical applications, Xenon Xe-133 serves as a valuable tool in biomedical research. It is used in preclinical studies to investigate physiological processes, drug delivery mechanisms, and the effects of radiation on biological systems. Its well-defined radioactive decay properties facilitate precise measurement and analysis in controlled experimental settings.

The efficacy of Xenon Xe-133 in these applications is directly tied to its isotopic purity, specific activity, and the ability of medical professionals to administer and image it accurately. The short half-life of Xenon Xe-133 (5.25 days) is advantageous for diagnostic imaging as it minimizes patient radiation exposure while providing sufficient time for imaging procedures.

What is the Patent Landscape for Xenon Xe-133 Production and Application?

The patent landscape for Xenon Xe-133 encompasses methods of production, purification, delivery systems, and novel applications. Analysis reveals trends in innovation and areas of potential intellectual property development.

Key Patenting Trends:

• Production and Purification Methods: Patents in this category focus on improving the efficiency and yield of Xenon Xe-133 production. This includes advancements in neutron activation techniques, target materials, and separation processes to obtain high-purity Xenon Xe-133. For example, patents might describe specific reactor configurations or irradiation parameters optimized for Xenon-132 activation.
• Delivery Systems and Devices: Innovation is evident in devices designed for the safe and effective administration of Xenon Xe-133 for inhalation or injection. This includes inhalation systems that control gas flow and concentration, specialized syringes for radioactive material handling, and closed-loop systems to minimize environmental release. Some patents may focus on disposable components to enhance safety and reduce cross-contamination.
• Diagnostic Imaging Techniques: Patents related to diagnostic applications often describe new imaging protocols, data processing algorithms, or combinations of Xenon Xe-133 with other imaging modalities to enhance diagnostic accuracy. This could involve software patents for image reconstruction or methods for quantifying lung or brain perfusion.
• Therapeutic Applications: As research into the therapeutic uses of Xenon Xe-133 progresses, patents are emerging in this area. These patents might cover specific treatment protocols, dosage regimens, or methods for targeting cancerous cells with Xenon Xe-133. For instance, a patent could claim a method of treating a specific cancer type by delivering a defined dose of Xenon Xe-133.
• Isotope Enrichment and Production Enhancement: Some patents may address methods for increasing the concentration of the stable Xenon-132 isotope, the precursor for Xenon Xe-133 production, thereby potentially improving the overall efficiency of the manufacturing process.

Notable Patent Areas:

A review of recent patent filings indicates a sustained interest in:

1. Enhanced Production Yields: Patents focusing on optimizing neutron flux and irradiation times to maximize the conversion of Xenon-132 to Xenon-133.
2. Improved Isotopic Purity: Methods to remove trace impurities and unwanted isotopes that could affect diagnostic quality or increase radiation dose.
3. Advanced Inhalation Devices: Designs for more ergonomic and accurate delivery systems for pulmonary ventilation studies, including those with integrated dose monitoring.
4. Biomarker Combination Imaging: Patents exploring the use of Xenon Xe-133 in conjunction with other radiotracers or imaging agents to provide more comprehensive diagnostic information, particularly in neurology and oncology.
5. Quality Control and Safety Systems: Innovations in real-time monitoring and containment systems for radioactive Xenon gas during production, transport, and clinical use.

The patent landscape suggests that while the core applications of Xenon Xe-133 are well-established, ongoing innovation centers on improving production efficiency, enhancing delivery systems for patient safety and diagnostic accuracy, and exploring novel therapeutic avenues.

How are Regulatory Frameworks Shaping Xenon Xe-133 Availability?

Regulatory frameworks play a crucial role in governing the production, distribution, and use of Xenon Xe-133, directly impacting its availability and accessibility for medical purposes. These regulations are designed to ensure safety, quality, and security.

• Nuclear Regulatory Oversight: In the United States, the Nuclear Regulatory Commission (NRC) and equivalent bodies in other countries regulate the possession, use, and transfer of radioactive materials, including Xenon Xe-133. Licenses are required for production facilities, distributors, and end-users, with strict adherence to radiation safety standards, waste disposal protocols, and security measures. The NRC's regulations, such as those found in Title 10 of the Code of Federal Regulations (10 CFR), outline specific requirements for licensing and operations.
• Good Manufacturing Practices (GMP): Pharmaceutical-grade Xenon Xe-133 must be produced under strict Good Manufacturing Practices (GMP) as defined by regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). GMP ensures that products are consistently produced and controlled according to quality standards. This includes rigorous quality control testing for isotopic purity, radiochemical purity, and freedom from pyrogens.
• Transportation Regulations: The transportation of radioactive materials is subject to stringent regulations by national and international bodies, such as the Department of Transportation (DOT) in the U.S. and the International Atomic Energy Agency (IAEA). These regulations dictate packaging, labeling, shipping documentation, and emergency response procedures to ensure safe transit from the producer to the medical facility.
• Medical Device Regulations: Devices used for the administration and imaging of Xenon Xe-133, such as inhalation systems and gamma cameras, are regulated as medical devices. These regulations, overseen by agencies like the FDA, ensure that the devices are safe and effective for their intended use. This includes performance standards and pre-market review processes.
• International Harmonization and Agreements: International agreements and the influence of organizations like the IAEA aim to harmonize regulatory approaches to radioactive materials. This facilitates the global trade and availability of isotopes like Xenon Xe-133, while maintaining consistent safety and security standards across different jurisdictions.

The complexity and stringency of these regulatory frameworks necessitate significant investment in compliance, specialized infrastructure, and trained personnel for all entities involved in the Xenon Xe-133 supply chain. Changes or updates in these regulations can directly affect production costs, lead times, and the overall market dynamics.

What are the Economic Factors Influencing Xenon Xe-133 Pricing and Supply?

The pricing and supply of Xenon Xe-133 are influenced by a confluence of economic factors, reflecting its status as a specialized medical isotope.

• Production Costs: The primary driver of Xenon Xe-133 cost is the expense associated with its production. This includes the operational costs of nuclear reactors for neutron irradiation, the procurement of enriched Xenon-132 targets, the complex purification processes, and the specialized facilities required for handling radioactive materials safely. The high capital investment in these facilities also contributes to the overall cost structure.
• Limited Supplier Base: As noted, the global supply of Xenon Xe-133 is concentrated among a few specialized producers. This limited competition can lead to higher pricing power for these suppliers. The barriers to entry for new producers are substantial, involving significant regulatory hurdles, technological expertise, and financial investment.
• Demand Fluctuations: While demand for Xenon Xe-133 in established applications like pulmonary imaging is relatively stable, surges in demand due to specific medical needs or research initiatives can impact pricing and availability. Conversely, shifts towards alternative imaging modalities or reductions in healthcare budgets can affect demand and, consequently, supply dynamics.
• Regulatory Compliance Costs: The ongoing costs associated with maintaining strict regulatory compliance, including licensing fees, safety audits, quality assurance programs, and waste management, are factored into the final price of Xenon Xe-133. These costs are substantial and essential for safe and legal operation.
• Transportation and Logistics: The specialized handling, packaging, and transportation of radioactive materials add significant logistical costs. This includes secure, temperature-controlled shipping and adherence to stringent international transport regulations, which can elevate the overall delivered price of the isotope to end-users.
• Geopolitical Factors and Reactor Availability: The availability of reliable nuclear reactors capable of producing medical isotopes can be influenced by geopolitical stability and national energy policies. Any disruptions to reactor operations, whether planned maintenance or unforeseen issues, can directly affect Xenon Xe-133 supply and, by extension, its price.
• Exchange Rates and Currency Fluctuations: For suppliers and purchasers operating in different economic regions, fluctuations in exchange rates can impact the effective cost of Xenon Xe-133.

The economic model for Xenon Xe-133 is characterized by high fixed costs for production and a premium for specialized handling and regulatory adherence. These factors collectively contribute to its relatively high price point compared to non-radioactive pharmaceutical ingredients.

Key Takeaways

• The supply of Xenon Xe-133 is consolidated among a few specialized global producers, including Isotrak, Navidea Biopharmaceuticals, Eckert & Ziegler Radiopharma GmbH, and entities with historical ties to Nordion.
• Primary medical applications of Xenon Xe-133 are diagnostic ventilation studies of the lungs and cerebral blood flow assessments, with emerging research into therapeutic uses.
• The patent landscape shows ongoing innovation in production methods, purification techniques, advanced delivery systems, and the exploration of new diagnostic and therapeutic applications.
• Stringent regulatory frameworks, including those from the NRC, FDA, and international bodies, govern all aspects of Xenon Xe-133, ensuring safety and quality but also contributing to market complexity and cost.
• Economic factors such as high production costs, a limited supplier base, regulatory compliance burdens, and specialized logistics significantly influence the pricing and availability of Xenon Xe-133.

Frequently Asked Questions

1. What is the typical shelf life of Xenon Xe-133? The typical shelf life of Xenon Xe-133 is dictated by its physical half-life of 5.25 days. Products are generally distributed with sufficient remaining activity for immediate diagnostic use, and are typically utilized within days of production.

2. Are there alternative isotopes used for lung ventilation studies? Yes, while Xenon Xe-133 is a primary agent, Krypton-81m (Kr-81m) is another radioisotope used for lung ventilation imaging. Kr-81m has a shorter half-life (13 seconds), requiring an on-site generator, and offers higher imaging energy, which can be advantageous in certain scenarios.

3. What are the primary radiation safety concerns when handling Xenon Xe-133? The primary radiation safety concerns involve inhalation of the radioactive gas and potential skin contamination. Proper ventilation, sealed source handling, and personal protective equipment are crucial to minimize exposure. Waste disposal also requires adherence to strict radioactive waste management protocols.

4. How does the cost of Xenon Xe-133 compare to other diagnostic radiopharmaceuticals? The cost of Xenon Xe-133 is generally higher than many common diagnostic radiopharmaceuticals due to the specialized production infrastructure, reactor time, and strict regulatory requirements associated with radioactive gas production and handling.

5. What is the impact of nuclear reactor availability on the Xenon Xe-133 supply chain? The availability of nuclear reactors capable of neutron irradiation is a critical bottleneck for Xenon Xe-133 production. Disruptions to reactor operations, whether for maintenance, fuel cycles, or unexpected shutdowns, can lead to temporary shortages and price increases in the Xenon Xe-133 market.

Citations

[1] U.S. Nuclear Regulatory Commission. (n.d.). Title 10 of the Code of Federal Regulations. Retrieved from https://www.nrc.gov/reading-rm/doc-collections/cfr/

[2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/current-good-manufacturing-practice-cgmp

[3] U.S. Department of Transportation. (n.d.). Hazardous Materials Regulations. Retrieved from https://www.phmsa.dot.gov/regulations/hazardous-materials-regulations

[4] International Atomic Energy Agency. (n.d.). Regulations for the Safe Transport of Radioactive Material. Retrieved from https://www.iaea.org/services/publications/regulations/transport-of-radioactive-material